Prosecution Insights
Last updated: November 20, 2026

Spacecraft Seven LLC

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 4 art units • 4 examiners • 2 of 4 (50%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Spacecraft Seven LLC has 4 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 4 distinct examiners and 4 distinct art units, so the docket spans separate technical and examination assignments.

MONTANARI, DAVID A is the busiest examiner, with 1 pending matter. Counsel should manage the matters independently and avoid assuming that one examiner’s approach governs the full portfolio.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
0
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (50%)
2
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (25%)
§102 only1 (25%)
Multi-statute (no §101)2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MONTANARI, DAVID A 1 64.7% +49.4%
SPENCER, ANDREA LYNNE MORRIS 1 16.7% +40.0%
MCLEOD, AFRICA MHAIRIE 1 58.6% +58.1%
CONNORS, ALEXANDRA F 1 23.9% +43.1%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18019393 ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF MCLEOD, AFRICA MHAIRIE 8d overdue
18019396 CSRP3 (CYSTEINE AND GLYCINE RICH PROTEIN 3) GENE THERAPY SPENCER, ANDREA LYNNE MORRIS —
17430107 GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE CONNORS, ALEXANDRA F —

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18019393 ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF MCLEOD, AFRICA MHAIRIE 8d overdue
18265421 TREATMENT OF DANON DISEASE MONTANARI, DAVID A 34d
18019396 CSRP3 (CYSTEINE AND GLYCINE RICH PROTEIN 3) GENE THERAPY SPENCER, ANDREA LYNNE MORRIS —
17430107 GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE CONNORS, ALEXANDRA F —

Top Art Units

Art UnitApps
1632 1
1631 1
1635 1
1634 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18265421 TREATMENT OF DANON DISEASE MONTANARI, DAVID A 1632 §102 Final Rejection 34d AI Ready Jun 05, 2023
18019396 CSRP3 (CYSTEINE AND GLYCINE RICH PROTEIN 3) GENE THERAPY SPENCER, ANDREA LYNNE MORRIS 1631 §103§112 Final Rejection — Pending Feb 02, 2023
18019393 ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF MCLEOD, AFRICA MHAIRIE 1635 §103§112 Final Rejection 8d overdue AI Ready Feb 02, 2023
17430107 GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE CONNORS, ALEXANDRA F 1634 §103 Final Rejection — Pending Aug 11, 2021

Managing Spacecraft Seven LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Spacecraft Seven LLC have?

Spacecraft Seven LLC has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.

Which USPTO examiner handles the most Spacecraft Seven LLC applications?

David A Montanari has the most, with 1 of Spacecraft Seven LLC's pending office actions.

What technology area are Spacecraft Seven LLC's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month